Biotech

AdBio partners’ unique strategy combines early-stage investments in promising startups and strong entrepreneurial support to enable and strengthen the company’s growth.

As an early-stage investor, we act as a catalyst to create companies based on innovations coming from academic research. We have established relationships with leading research institutions and technology transfer offices in Europe and benefit from the support of strong network of scientific, clinical, industry and financial partners.

The operational team is managed by Alain Huriez, MD, Chairman and Managing Partner, and Clément Bertholet, Managing Partner. The team includes seasoned investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific, medical and operational expertise.

Therapeutic focus

Biotech

Early-stage investor into companies developing therapeutics and therapeutic platforms in the advanced therapies with a focus on CGT and related technologies.

Raising seed to Sr A; therapeutics, cell and gene therapies or related, e.g. in vivo CAR, etc.

Biotech

Life Sciences investor

Strong management team; quality of the assets, IP & scientific team

Biotech

Amplitude Ventures is a capital catalyst for highly innovative companies at the point of value acceleration. We work with the most promising healthcare companies that share our vision of bringing groundbreaking technologies to patients. Amplitude is building world-class companies in precision medicine and next-generation medical devices.

Since 2012, the Amplitude team has deployed a venture growth model used to build Canadian companies with world-class management teams and scale companies to breakout potential. This model has been used by the team to create, build, and grow companies, resulting in over $6 billion in company value.

Seed to Series A biotechnology focused

Pharma

Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceutical products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.

In-Licensing, collaborations, partnerships, and acquisitions of late stage, submission ready, or marketed products across our core TAs including Oncology, Ophthalmology, Specialty CNS, Women's Health, and Dermatology in Canada, the US, and LATAM. We will be opportunistic across other TAs

Biotech

Biotech VC focused on therapeutics

Preclinical with a drug candidate nominated, raising for a clinical PoC

Pharma

Family office, experienced life sciences executive and entrepreneur

Interested in CNS, opthalmology, rare disease and women's health opportunities in clinical stage

Biotech

Family Office

Status, Financials, Investment Request, Prospectus and Term Sheet is prepared

Biotech

Bloom Burton & Co. is a Toronto-based investment banking and advisory firm focused exclusively on the healthcare and life-sciences sector. Founded in 2008, the firm works with healthcare companies and investors to accelerate the development, financing, and commercialization of innovative medical technologies

No specific requirements, just the most compelling opportunities.

Biotech

BoxOne Ventures is a Montreal early stage investment fund investing across deep tech

Life Sciences

Biotech

BSQUARED Capital is a biotech-focused family office fund started in late 2023 by Roberto and Carlo Bellini. We invest in companies developing therapeutics in late preclinical or clinical stage with a disease- and modality-agnostic mindset.

Companies we are looking for
- Therapeutics companies only
- Late preclinical or clinical stage

Biotech

CCRM Enterprises invests in early-stage ventures and projects that are developing therapeutics and enabling technologies. Through an extensive network of investors, it can bring together risk capital to support these early-stage ventures as they scale-up and advance along the development pathway. By tapping into CCRM’s manufacturing infrastructure and expertise, CCRM Enterprises provides capital-efficient support to accelerate and de-risk these high potential, early-stage ventures, further enabling the development of an advanced therapies ecosystem.

Advanced therapy

Other

Early stage VC - healthtech, techbio, aging biology ++.

Deep bio+ tech expertise. Large global target problem. Early validation.

Pharma

Covar Pharmaceuticals specializes in the contract development of small-molecule NCEs, 505(b)(2) products, and complex generics, including formulation development, clinical supply manufacturing, and regulatory strategy and submissions. Our Health Canada–approved site is located in Mississauga, Ontario.

Innovative companies developing small molecule drugs. We are also interested in connecting with investors which may be interested in identifying pre-clinical to Phase 1 assets on the behalf of our clients.

Biotech

CPDC is actively seeking direct Seed and Series A investments, in-licensing and collaboration opportunities in the radiopharmaceutical space.
As dedicated partners, we bring sector expertise and a robust network to collaborate with management teams, enhancing value and advancing the impact of radiopharmaceutical-focused innovation.

Seed, Series A
Radiopharma therapeutics, diagnostics and enabling technologies

Biotech

CQDM is a non-profit biopharmaceutical research consortium whose mission is to support and facilitate multi-stakeholder collaborative R&D that accelerates translation of leading-edge discoveries into vaccines, therapeutics and diagnostics addressing unmet medical needs while generating significant benefits for the Canadian economy.

Early stage companies with platform technologies looking to connect with our 11 global paharma members

Biotech

CTI Life Sciences Fund is a leading Canadian biotech VC fund investing in Canada, US and Europe. Our investment thesis centers around catalyzing and transforming investments through our hands-on approach. We are therapeutic and modality agnostic, deploying companies developing best-in-class or first-in-class therapeutics addressing real medical unmet needs and commercial potential

Biotherapeutics company

Biotech

EKS Ventures is an advisory and venture studio firm based in Toronto. We create value and build strong companies based on relationships with customers, financiers, research, clinical development, and commercial partners. By actively listening, asking questions, and focusing on people, EKS empowers companies to make the best possible decisions and executes commercial plans. Our combined expertise across multiple therapeutic modalities positions us uniquely to support companies in value creation. EKS is composed of seasoned executives with a combined 50+ years of experience in the pharmaceutical and biotechnology industries.

We would like to meet with companies looking towards their next value infection point and work with a team who can drive this value creation step. We are particularly interested in building a portfolio of assets in the area of muscle health and muscle biology.

Pharma

https://www.lilly.com

I focus on neuro but also happy to meet with oncology, immunology, and cardio metabolic companies. I like AI companies with application in Pharma field.